RCKT
Rocket Pharmaceuticals Inc
3.40$
+0.0%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1,952.9% | +14.4% | -21.5% | +146.9% | +48.1% | +58.8% | -15.9% | +11.0% | +2.6% | -6.8% | -37.4% | |
| – | +3,005.7% | +14.2% | -21.3% | +106.9% | +47.2% | +58.4% | -19.6% | -7.1% | +3.9% | 0.0% | -49.0% | |
| – | +2,112.3% | -62.8% | +164.2% | +41.5% | +66.5% | +60.3% | -21.7% | -39.6% | -60.2% | +192.7% | -52.6% | |
| – | +2,975.7% | +13.7% | -20.9% | +105.7% | +47.8% | +58.7% | -19.5% | -8.3% | +4.7% | -0.2% | -49.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +39.2% | -50.2% | +260.0% | +1,345.2% | -34.4% | +276.7% | +7.3% | – | – | – | |
| – | – | – | – | – | +0.0% | +0.0% | +0.0% | +27.1% | +0.0% | +0.0% | +0.0% | |
| – | – | – | – | – | – | – | – | – | -2.2% | +0.0% | +0.0% | |
| – | -92.1% | +1,152.9% | -4.4% | +6.0% | +13.2% | +34.7% | -51.6% | +46.9% | +18.7% | -12.6% | -17.4% | |
| – | +11.8% | +74.2% | -43.6% | +277.7% | +19.1% | +78.1% | -32.0% | +76.7% | +23.8% | -16.1% | -25.8% | |
| – | -100.0% | – | – | – | +162,378.8% | +646.6% | -64.3% | -1.7% | +8.3% | +5.2% | +2.0% | |
| – | +42.5% | -2.5% | -71.7% | -99.9% | -42.3% | +145.6% | -42.3% | +7,605,709.1% | -100.0% | +91,604.3% | – | |
| – | -100.0% | – | +1.2% | -16.3% | +8.7% | -22.2% | – | – | – | – | – | |
| – | – | -32.8% | -34.7% | +306.2% | +58.4% | +63.9% | -9.7% | +7.7% | +0.6% | -6.0% | -40.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +214.0% | +1.2% | +1.2% | +482.0% | +24.5% | +13.0% | +14.2% | +7.8% | +23.3% | +12.9% | +17.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.